Tempus AI has an immunology risk testing product ready for researchers to test out and is working with Cleveland Clinic on better ways to assess how immunotherapy might work on patients. The ...

Tempus AI's diagnostics segment shows strong pricing power, with Oncology ASP rising from $1,630 to over $2,200. Read why TEM ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...

July 9 (Reuters) - Wall Street brokerages started covering SoftBank Group-backed Tempus AI (TEM.O), opens new tab on a bullish note on Tuesday, betting that the company's AI-powered library of ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher by 7.45% to $35.82 during Tuesday’s session after the company announced it was granted Advanced Diagnostic Laboratory Test (ADLT) status for its ...

Tempus AI TEM continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay ...

Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care ...

Tempus AI has expanded its relationship with Personalis, investing $36 million in the oncology biotech and becoming the exclusive commercial partner for its test to detect minimal residual disease, or ...